<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>News on endoscout</title><link>https://www.endoscout.de/news/</link><description>Recent content in News on endoscout</description><generator>Hugo -- gohugo.io</generator><language>de-de</language><lastBuildDate>Sat, 13 Apr 2019 10:57:26 +0200</lastBuildDate><atom:link href="https://www.endoscout.de/news/index.xml" rel="self" type="application/rss+xml"/><item><title/><link>https://www.endoscout.de/news/risk-of-death-following-application/</link><pubDate>Sat, 13 Apr 2019 10:57:26 +0200</pubDate><guid>https://www.endoscout.de/news/risk-of-death-following-application/</guid><description>Alvimedica NiTiDES @ CIRSE 2018 NiTiDES is a polymer free stent-eluting the amphilimus formulation (a combination of sirolimus and fatty acid) through the “Abluminal Reservoir Technology” aiming at obtaining the highest efficacy profile for the patient. The polymer-free platform, which is made of nitinol, is integrally covered by the Bio Inducer Surface coating, a second generation pure carbon “ultra thin” layer that drastically increases haemo- and biocompatibility.
Alvimedica NiTiDES – Platform characteristics / Dr.</description></item><item><title/><link>https://www.endoscout.de/news/meta-analysis-observes-increased-mortality/</link><pubDate>Sat, 13 Apr 2019 10:52:30 +0200</pubDate><guid>https://www.endoscout.de/news/meta-analysis-observes-increased-mortality/</guid><description>EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018 London, April 25th, 2018 – EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018.
The 12-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented for the first time at CX Symposium 2018 at the DCB session on April 24th.
Main objective was to assess the effectiveness of Luminor drug coated balloon (DCB) vs.</description></item><item><title/><link>https://www.endoscout.de/news/2-year-mortality-effpac/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/2-year-mortality-effpac/</guid><description>https://pubs.rsna.org/doi/10.1148/radiol.2020201370</description></item><item><title/><link>https://www.endoscout.de/news/analysis-of-german-insurance-data-shows-no-long-term-increased-mortality-with-paclitaxel-based-devices/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/analysis-of-german-insurance-data-shows-no-long-term-increased-mortality-with-paclitaxel-based-devices/</guid><description>A real-world analysis of 9.2 million patients included in a German insurance database showed no evidence for increased mortality associated with paclitaxel-based drug-eluting devices (DEDs) during 11 years of use in endovascular revascularization (EVR) of peripheral vessels. The findings from the analysis were published by Eva Freisinger, MD, et al in European Heart Journal.
According to the investigators, the study sought to address the safety concerns raised by recently published data that indicated a two-fold increase in long-term mortality in patients treated with these devices.</description></item><item><title/><link>https://www.endoscout.de/news/bvmed-paclitaxel-beschichtete-ballonkatheter-und-stents-bleiben-eine-prim%C3%A4re-therapieoption/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/bvmed-paclitaxel-beschichtete-ballonkatheter-und-stents-bleiben-eine-prim%C3%A4re-therapieoption/</guid><description>Paclitaxel-beschichtete Ballonkatheter und Stents bleiben eine primäre Therapieoption bei pAVK-Patienten mit hohem Restenoserisiko oder Restenosen BVMed zur peripheren Gefäßmedizin 10.09.2019|72/19|Berlin|
Paclitaxel-beschichtete Produkte wie beschichtete Ballonkatheter (DCB) oder Medikament-freisetzende Stents (DES) bleiben eine primäre Therapieoption für Patienten mit peripherer arterieller Verschlusskrankheit (pAVK) und hohem Restenoserisiko oder Restenosen. Darauf haben Experten des BVMed-Fachbereichs &amp;ldquo;Periphere Gefäßmedizin&amp;rdquo; vor dem Hintergrund jüngster Empfehlungen der US-amerikanischen Gesundheitsbehörde (FDA) hingewiesen. In den letzten Monaten hatte eine griechische Metaanalyse von Dr.</description></item><item><title/><link>https://www.endoscout.de/news/effpac-24-month-outcomes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/effpac-24-month-outcomes/</guid><description>Effectiveness of LuminorDCB vs. POBA in the SFA:24-month safety and efficacy outcomes Paris, May 21st, 2019 – EFFPAC RCT 24-month outstanding results with Luminor DCB have been revealed at EuroPCR 2019.
The 24-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented for the first time at EuroPCR 2019 on May 21st.
Main objective was to assess the effectiveness of Luminor drug coated balloon (DCB) vs.</description></item><item><title/><link>https://www.endoscout.de/news/effpac-42-month-outcomes/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/effpac-42-month-outcomes/</guid><description/></item><item><title/><link>https://www.endoscout.de/news/empfehlungen-bfarm-dcb-des/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/empfehlungen-bfarm-dcb-des/</guid><description>Empfehlung für die Verwendung von Paclitaxel-beschichteten Stents (DES) und Ballons (DCB) in der Behandlung der peripheren arteriellen Verschlusskrankheit (pAVK) Referenz-Nr.: 00092/19
Im Dezember 2018 wurde von Katsamos et al. im Journal of American Heart Association eine Meta-Analyse* randomisierter kontrollierter Studien veröffentlicht. Die Analyse konzentrierte sich auf Paclitaxel-beschichtete Ballons und Stents, die in Oberschenkel- und Kniekehlenarterien bei Patientinnen und Patienten mit intermittierender Claudicatio eingesetzt wurden. Die Autoren kamen zu dem Ergebnis, dass Patientinnen / Patienten, bei denen diese Produkte eingesetzt wurden, 2 bis 5 Jahre nach deren Anwendung eine statistisch signifikant erhöhte Sterbewahrscheinlichkeit (Gesamtmortalität) im Vergleich zu Patientinnen / Patienten aufwiesen, die mit unbeschichteten Ballons oder Bare-Metal-Stents behandelt wurden.</description></item><item><title/><link>https://www.endoscout.de/news/incidental-findings-erectyle-dysfunction/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/incidental-findings-erectyle-dysfunction/</guid><description>Incidental findings during computed tomographicangiography diagnostic work-up in patients witharteriogenic erectile dysfunction:
&amp;raquo; Official Article Swiss Medical Weekly &amp;laquo;
Summary
AIM: To analyse the incidental findings during computertomographic angiography (CTA) diagnostic work-up in patients with arteriogenic erectile dysfunction (ED).
PATIENTS AND METHODS: The medical records of all patients with suspected arteriogenic ED were entered into a database. Risk factors and underlying comorbidities were also collected. Pathological CTA findings were extracted from the CT readings and entered into the data-base.</description></item><item><title/><link>https://www.endoscout.de/news/mortality-not-correlated-withpaclitaxel-exposure/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/mortality-not-correlated-withpaclitaxel-exposure/</guid><description>Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon &amp;raquo; DOWNLOAD FULL ARTICLE &amp;laquo;
Background
Five years of prospective clinical trials confirm that the paclitaxel drug-coated balloon (DCB) (IN.PACT Admiral, Medtronic, Dublin, Ireland) is safe and effective to treat femoropopliteal artery disease. A recent meta-analysis of heterogeneous trials of paclitaxel-based balloons and stents reported that they are associated with increased mortality and that higher doses are linked to higher mortality from 2 to 5 years.</description></item><item><title/><link>https://www.endoscout.de/news/novel-paclitaxel-nano-coated-balloon-achieves-lower-incidence-of-restenosis-than-plain-balloon-angioplasty-at-two-years/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/novel-paclitaxel-nano-coated-balloon-achieves-lower-incidence-of-restenosis-than-plain-balloon-angioplasty-at-two-years/</guid><description>Two-year results of EffPac—a randomised controlled trial to assess the safety and efficacy of a novel drug-coated balloon (DCB) with a nanotechnology coating—have been announced. The investigators, Ulf Teichgräber (University Hospital Jena, Germany) and colleagues, report that use of the DCB in question, iVascular’s Luminor, resulted in a significantly lower incidence of binary restenosis compared to percutaneous transluminal angioplasty (PTA).
The new data, presented for the first time at the Annual Scientific Meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE 2019; 7–11 September, Barcelona, Spain), also showed a significant clinical and haemodynamic improvement from baseline, similar to the level of improvement achieved with POBA, but with considerably fewer repeat revascularisations.</description></item><item><title/><link>https://www.endoscout.de/news/tintin-1-year-outcomes./</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/tintin-1-year-outcomes./</guid><description>TINTIN is a physician initiated, prospective, single arm multicenter, Belgian trial, that investigates the safety and efficacy of the treatment with luminor DCB and iVolution self-expanding stent in TASC C and D femoropopliteal lesions of 240mm average.
The 1-year clinical outcomes of TINTIN Trial were presented at LINC 2020 by Dr Koen Deloose (Dendermonde, Belgium) who stated, during his presentation, that: “The combination of luminor DCB and iVolution self-expanding stent, shows impressive 1-year outcomes in the TINTIN trial, comparable to DEs but in more complex lesions”.</description></item><item><title/><link>https://www.endoscout.de/news/zweitmeinung-amputation-diabetisches-fusssyndrom/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://www.endoscout.de/news/zweitmeinung-amputation-diabetisches-fusssyndrom/</guid><description>Amputation beim Diabetischen Fußsyndrom: Patientinnen und Patienten können ärztliche Zweitmeinung zur empfohlenen Operation einholen. Berlin, 16. April 2020 – Patientinnen und Patienten mit Diabetischem Fußsyndrom können sich vor einer Amputation an den unteren Extremitäten zukünftig eine unabhängige ärztliche Zweitmeinung einholen. Hierbei überprüft ein qualifizierter Zweitmeiner die medizinische Notwendigkeit des geplanten Eingriffs und berät zu konservativen und weniger invasiven Behandlungsmöglichkeiten. Die entsprechende Ergänzung der Richtlinie zum Zweitmeinungsverfahren beschloss der Gemeinsame Bundesausschuss (G-BA) am Donnerstag in Berlin.</description></item></channel></rss>